US2020316099A1PendingUtilityA1

Isotopologues of 5-azacytidine

72
Assignee: CELGENE CORPPriority: May 15, 2008Filed: Mar 27, 2020Published: Oct 8, 2020
Est. expiryMay 15, 2028(~1.8 yrs left)· nominal 20-yr term from priority
Inventors:John F. TraverseWilliam W. LeongJeffrey B. EtterMei LaiJay Thomas Backstrom
A61P 43/00A61K 31/706A61K 9/28A61K 47/26A61K 9/20A61K 9/2846A61K 9/2866A61K 31/7068A61K 9/2886A61K 9/2013A61K 9/2018A61K 47/10
72
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.

Claims

exact text as granted — not AI-modified
1 . (canceled) 
     
     
         2 . A compound of the formula: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt or solvate thereof, wherein: 
         Y 4  is a hydrogen isotopically enriched with deuterium, and Y 1 , Y 2 , Y 3 , Y 5 , Y 6 , and Y 7  are non-enriched hydrogen atoms.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.